DGHS Hatchet Chops Ivermectin Nationally While Positioning Unproven Tocilizumab Despite Success of Uttar Pradesh—How will ICMR & AIMS Weigh In?

DGHS Hatchet Chops Ivermectin Nationally While Positions Unproven Tocilizumab Despite Success of Uttar Pradesh—How will ICMR & AIMS Weigh In

Power, politics, and economics are alive and well in India as apparently as quickly as select national health authorities in the world’s most second populated nation and fifth largest economy as measured by gross domestic product (GDP) included ivermectin in the national guidelines, the recommendation was just as quickly rescinded despite what appears to be tremendous success in states such as Uttar Pradesh, as TrialSite has recently reported. TrialSite has chronicled a remarkable turnaround that’s included the use of ivermectin and doxycycline-based home medicine kits in Uttar Pradesh and a few other states. On April 22, the use of ivermectin was formalized at the national level by All Institute of India Medical Science (AIIMS) and the Indian Council of Medical Research (ICMR) as reported in TrialSite. But in a national movement to hatchet that recommendation, the Union Health Ministry and Family Welfare’s directorate general of health services known as DGHS changed the guidelines again to cease use of Ivermectin and Doxycycline for COVID-19 treatment, dropping all medicines except for antipyretic and antitussives for asymptomatic and mild cases, reports local media. But this see...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee